| 徐 晶,白 净,邢玉洁,马美娟,唐治国.左西孟旦联合曲美他嗪对心衰介入治疗术后患者血清galectin-3和syndecan-4表达水平及心功能的影响[J].现代生物医学进展英文版,2021,(24):4747-4750. |
| 左西孟旦联合曲美他嗪对心衰介入治疗术后患者血清galectin-3和syndecan-4表达水平及心功能的影响 |
| The Effects of Levosimendan Combined with Trimetazidine on Serum Galectin-3 and Syndecan-4 Expression and Cardiac Function in Patients with Heart Failure after Interventional Therapy |
| Received:May 06, 2021 Revised:May 31, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.24.030 |
| 中文关键词: 左西孟旦 曲美他嗪 心力衰竭 人多配体蛋白聚糖4 半乳糖凝集素 心功能 |
| 英文关键词: Levosimendan Trimetazidine Heart failure Human polyligand proteoglycan 4 Galectin Cardiac function |
| 基金项目:陕西省自然科学基础研究计划项目（2019JM-530）；陕西省分子心脏病学重点实验室开放课题基金项目（KLMC-2018-04） |
|
| Hits: 601 |
| Download times: 351 |
| 中文摘要: |
| 摘要 目的：探讨左西孟旦联合曲美他嗪对心衰（heart failure，HF）介入治疗术后患者血清半乳糖凝集素3（galectin-3）和人多配体蛋白聚糖4（syndecan-4）表达水平及心功能的影响。方法：2018年9月到2021年1月选择在本院完成介入治疗术的心衰患者108例，根据随机信封抽签原则把其分为联合组与对照组各54例。对照组给予左西孟旦治疗，联合组给予左西孟旦联合曲美他嗪治疗，两组都治疗观察1个月。结果：治疗后联合组的总有效率为98.1%，高于对照组的88.9%（P<0.05）。两组治疗后的左心室舒张末期内径（Left ventricular end diastolic diameter，LVEDD）、左心室收缩末期内径（Left ventricular end systolic diameter，LVESD）都低于治疗前（P<0.05），联合组低于对照组（P<0.05）。两组治疗后的血清galectin-3和syndecan-4含量低于治疗前（P<0.05），联合组低于对照组（P<0.05）。治疗后随访6个月，联合组的再住院率与死亡率为9.3%和3.7%，低于对照组的27.8%和14.8%（P<0.05）。结论：左西孟旦联合曲美他嗪对心衰介入治疗术后患者的应用能抑制血清galectin-3和syndecan-4表达水平，改善患者的心功能，提高治疗效果，降低患者的随访再住院率与死亡率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of levosimendan combined with trimetazidine on serum galectin-3 and syndecan-4 expression and cardiac function in patients with heart failure after interventional therapy. Methods: From September 2018 to January 2021, 108 cases of patients with heart failure who completed interventional therapy in Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital were selected and were divided into the combination group and levosimendan group with 54 cases each groups according to the principle of random envelope drawing. The levosimendan group were given levosimendan treatment, and the combination group were given levosimendan combined with trimetazidine treatment. Both groups were treated and observed for 1 month. Results: After treatment, the total effective rate of the combination group were 98.1%, which were higher than 88.9% of the levosimendan group(P<0.05). After treatment, the left ventricular end diastolic diameter(LVEDD) and left ventricular end systolic diameter (LVESD) of the combination group and the levosimendan group were lower than before treatment(P<0.05), and the combination group were lower than the levosimendan group(P<0.05). Serum galectin-3 and syndecan-4 levels after treatment in the the combination group and the levosimendan group were lower than before treatment(P<0.05), and the combination group were lower than the levosimendan group(P<0.05). Followed-up for 6 months after treatment, the rehospitalization rate and mortality rate of the combination group were 9.3% and 3.7%, which were lower than the 27.8% and 14.8% of the levosimendan group (P<0.05). Conclusion: The application of levosimendan combined with trimetazidine in patients with heart failure after interventional therapy can inhibit the expression of serum galectin-3 and syndecan-4, improve the patient's cardiac function, improve the treatment effect, and reduce the follow-up and rehospitalization of the patient Rate and mortality. |
|
View Full Text
View/Add Comment Download reader |
| Close |
